Congenital Spindle-Cell Rhabdomyosarcoma with TEAD1-NCOA2 Fusion: Case Report and Review of the Literature
Current Oncology · 27.10.2026 · 33 (11) · 649
DOI: 10.3390/curroncol33110649 ↗Kurz gefasst
Fallbericht in der Zeitschrift Current Oncology, online erschienen am 27.10.2026. Verfasst von Alessia Pancaldi und 9 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Spindle-cell and sclerosing rhabdomyosarcomas (ssRMSs) are recently described as a rare variant of rhabdomyosarcoma (RMS), categorized by the World Health Organization classification as a entity distinct from embryonal or alveolar RMSs. Recent studies have shown ssRMSs to be a group of entities with significant morphological overlap but with a great molecular heterogeneity, with some genetic alterations potentially offering a better prognosis. Tumors harboring MYOD1 (p.L122R) mutations usually occur in older children and have a poorer prognosis, while tumors with genetic translocations resulting in fusion genes involving NCOA2 and/or VGLL2 tend to be congenital. Reports in the literature mainly suggest a favorable prognosis for this subset; however, four cases of patients who experienced local progression and distant metastases have recently been described. Outcomes and best treatment options for this subset of patients are therefore not fully established.
Methods
We reviewed the current literature about treatment and outcomes of ssRMSs in infants using the PubMed CENTRAL databases, including in our literature search papers published in English in the last ten years.
Results
We present a very rare case of a 15-month-old female diagnosed with a spindle-cell rhabdomyosarcoma harboring TEAD1-NCOA2 fusion of the left scapular region. The patient showed no local recurrence at the last follow-up, 4 years after being treated with chemotherapy and surgery. Our literature search identified 1323 records, of which 21 were included in the review.
Conclusions
Our case report confirms the few data previously published in the literature, suggesting a good prognosis for this subset of patients. Molecularly defined ssRMSs in infants likely represent a biologically distinct entity which may not require the aggressive multimodal treatment used for other subtypes of rhabdomyosarcoma.
Zitieren
APA
Pancaldi, A., Lecis, M., Evangelisti, E., Mariotti, I., Garcinuno, M. D. C. C., Righi, A., Errani, C., Iughetti, L., Palazzi, G., & Predieri, B. (2026). Congenital Spindle-Cell Rhabdomyosarcoma with TEAD1-NCOA2 Fusion: Case Report and Review of the Literature. Current Oncology, 33(11), 649. https://doi.org/10.3390/curroncol33110649
Vancouver
Pancaldi A, Lecis M, Evangelisti E, Mariotti I, Garcinuno MDCC, Righi A, et al. Congenital Spindle-Cell Rhabdomyosarcoma with TEAD1-NCOA2 Fusion: Case Report and Review of the Literature. Current Oncology. 2026;33(11):649. doi:10.3390/curroncol33110649
BibTeX
@article{Pancaldi2026,
author = {Pancaldi, Alessia and Lecis, Marco and Evangelisti, Elena and Mariotti, Ilaria and Garcinuno, Maria del Carmen Cano and Righi, Alberto and Errani, Costantino and Iughetti, Lorenzo and Palazzi, Giovanni and Predieri, Barbara},
title = {Congenital Spindle-Cell Rhabdomyosarcoma with TEAD1-NCOA2 Fusion: Case Report and Review of the Literature},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {11},
pages = {649},
doi = {10.3390/curroncol33110649}
}
EUVIMED